It is made available under a CC-BY-NC-ND 4.0 International license .

A novel cortical biomarker signature predicts individual pain sensitivity

- 2 Nahian S Chowdhury PhD*^{1,2}, Chuan Bi PhD*^{3, 4}, Andrew J Furman PhD^{5,6}, Alan KI Chiang
- 3 PhD^{1,2}, Patrick Skippen PhD^{1,7,8}, Emily Si MSc¹, Samantha K Millard PhD^{1,2}, Sarah M
- 4 Margerison BA^{5,6}, Darrah Spies BSc^{5,6}, Michael L Keaser BA^{5,6} Joyce T Da Silva PhD^{5,6},
- 5 Shuo Chen PhD³, Siobhan M Schabrun PhD^{**9,10}, David A Seminowicz PhD^{**5,6,11}
- 6 *Co-first author
- 7 **Co-senior author
- ⁸ ¹Center for Pain IMPACT, Neuroscience Research Australia, Sydney, New South Wales,
- 9 Australia

1

- ²University of New South Wales, Sydney, New South Wales, Australia
- ³Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public
- 12 Health, University of Maryland School of Medicine

⁴Division of Biostatistics, Center for Devices and Radiological Health, U.S. Food and Drug

- 14 Administration, USA
- ⁵Department of Neural and Pain Sciences, University of Maryland School of Dentistry,
- 16 Baltimore, USA
- ⁶Center to Advance Chronic Pain Research, University of Maryland Baltimore, USA
- ⁷Data Sciences, Hunter Medical Research Institute, Newcastle, NSW, Australia
- ¹⁹ ⁸School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
- ⁹The Gray Centre for Mobility and Activity, Parkwood Institute, St. Joseph's Healthcare
- 21 London, Canada
- ¹⁰School of Physical Therapy, University of Western Ontario, London, Canada
- ²³ ¹¹Department of Medical Biophysics, Schulich School of Medicine & Dentistry, University
- 24 of Western Ontario, London, Canada
- 25
- 26 Date of Revision: 09/21/2024
- 27 Word Count: 2990
- 28 Keywords: Pain, Biomarker, Electroencephalography, Transcranial Magnetic Stimulation
- 29

30 **Corresponding Author:**

- 31 Professor David A Seminowicz
- 32 Department of Medical Biophysics
- 33 Schulich School of Medicine & Dentistry
- 34 University of Western Ontario, London, Canada,
- 35 E-mail: dseminow@uwo.ca
- 36
- 37
- 38
- 39

It is made available under a CC-BY-NC-ND 4.0 International license .

41	Key Points
42	Question: Can individuals be accurately classified as high or low pain sensitive based on two
43	features of cortical activity: sensorimotor peak alpha frequency (PAF) and corticomotor
44	excitability (CME)?
45	Findings: In a cohort study of 150 healthy participants, the performance of a logistic
46	regression model was outstanding in a training set (n=100) and excellent in a test set (n=50),
47	with the combination of slower PAF and CME depression predicting higher pain. Results
48	were reproduced across a range of methodological parameters, and inclusion of covariates did
49	not improve model performance
50	Meaning: A novel cortical biomarker comprised of PAF and CME can accurately distinguish
51	high and low pain sensitive individuals
52	
53	
54	
55	
56	
57	
57	
58	
59	
60	
61	

It is made available under a CC-BY-NC-ND 4.0 International license .

6	2
-	_

Abstract

63	Background: Biomarkers would greatly assist chronic pain management. The present study
64	aimed to undertake analytical validation of a sensorimotor cortical biomarker signature for
65	pain consisting of two measures: sensorimotor peak alpha frequency (PAF) and corticomotor
66	excitability (CME), using a human model of prolonged temporomandibular pain (masseter
67	intramuscular injection of nerve growth factor [NGF]).
68	Methods: 150 participants received an injection of NGF to the right masseter muscle on Days
69	0 and 2, inducing prolonged pain lasting up to 4 weeks. Electroencephalography (EEG) to
70	assess PAF and transcranial magnetic stimulation (TMS) to assess CME were recorded on
71	Days 0, 2 and 5. We determined the predictive accuracy of the PAF/CME biomarker
72	signature using a nested control-test scheme: machine learning models were run on a training
73	set (n = 100), where PAF and CME were predictors and pain sensitivity was the outcome.
74	The winning classifier was assessed on a test set $(n = 50)$ comparing the predicted pain labels
75	against the true labels.
76	Results: The winning classifier was logistic regression, with an outstanding area under the
77	curve (AUC=1.00). The locked model assessed on the test set had excellent performance
78	(AUC=0.88). Results were reproduced across a range of methodological parameters.
79	Moreover, inclusion of sex and pain catastrophizing as covariates did not improve model
80	performance, suggesting the model including biomarkers only was more robust. PAF and
81	CME biomarkers showed good-excellent test-retest reliability.
82	Conclusions: This study provides evidence for a sensorimotor cortical biomarker signature
83	for pain sensitivity. The combination of accuracy, reproducibility, and reliability, suggests the
84	PAF/CME biomarker signature has substantial potential for clinical translation.

It is made available under a CC-BY-NC-ND 4.0 International license .

85 Several objective pain biomarkers have been proposed, including neuroimaging markers of mechanistic/structural abnormalities¹⁻³, neural oscillatory rhythms⁴ and "multi-86 omics" metrics of micro RNA⁵, proteins⁶, lipids and metabolites⁷. Such biomarkers would 87 greatly assist decision making in the diagnosis, prevention and treatment of chronic pain⁸. 88 89 However, attempts at establishing pain biomarkers have suffered from either insufficient sample sizes to conduct full-scale analytical validation using machine learning⁸⁻¹⁰, failure to 90 use clinically relevant pain models¹¹⁻¹³ or lack of assessment of reproducibility or test-retest 91 reliability^{14,15}. These factors have hindered the clinical translatability of prospective pain 92 93 biomarkers.

94 Research suggests that the neural oscillatory rhythms involved in processing 95 nociceptive input, and the corticospinal signalling involved in the subsequent motor response, are both critical in shaping the subjective experience of $pain^{4,16}$. This work has culminated to 96 97 the identification of a promising sensorimotor cortical biomarker signature for predicting pain sensitivity involving two metrics: 1) sensorimotor peak alpha frequency (PAF), defined as the 98 dominant sensorimotor cortical oscillation in the alpha (8-12Hz) range¹⁷ and 2) corticomotor 99 100 excitability (CME), defined as the efficacy at which signals are relayed from primary motor cortex (M1) to peripheral muscles¹⁸. Previous work has shown that slower PAF prior to pain 101 102 onset and reduced CME during prolonged pain ("depression") are associated with more pain, while faster PAF and increased CME ("facilitation") are associated with less pain¹⁹⁻²³. Given 103 104 individuals who experience higher pain in the early stages of a prolonged pain episode (e.g. post-surgery) are more likely to develop chronic pain in the future²⁴, slow PAF prior to an 105 106 anticipated prolonged pain episode and/or CME depression during the acute stages of pain 107 could be predictors for the transition to chronic pain.

This paper presents the main outcomes of the PREDICT trial, a pre-registered
 (NCT04241562²⁵) analytical validation of the PAF/CME biomarker signature using a model

It is made available under a CC-BY-NC-ND 4.0 International license . 110 of prolonged myofascial temporomandibular pain (masseter intramuscular injection of nerve 111 growth factor [NGF]). Repeated NGF injections induce progressively developing prolonged pain lasting up to 4 weeks^{23,26}, and has been shown to mimic chronic pain characteristics such 112 113 as time course (gradual development), type of pain (movement-evoked), functional 114 impairments, hyperalgesia (decreased pressure pain thresholds) and mechanism of sensitization^{27,28}. This makes the NGF model a highly standardised prolonged pain model 115 116 with which to undertake biomarker validation. 117 The aim of the PREDICT trial was to determine whether individuals could be 118 accurately classified as high or low pain sensitive based on baseline PAF and CME 119 facilitator/depressor classification. We predicted the area under the curve (AUC) of the 120 receiver operator characteristic (ROC) curve for distinguishing high and low pain sensitive individuals would be at least 70% (which represents an acceptable AUC)²⁹. 121 122 **Methods** 123 124 **Participants** 125 The PREDICT trial enrolled 159 healthy participants (70 females, 89 males, mean age 126 25.1 ± 6.1), with 150 participants remaining after dropouts. Ethical approval was obtained 127 from the University of New South Wales (HC190206) and the University of Maryland 128 Baltimore (HP-00085371). Written, informed consent was obtained. The supplementary 129 appendix contains all additional details regarding participant characteristics and 130 methodology. 131

It is made available under a CC-BY-NC-ND 4.0 International license .

133 Experimental Protocol

134 Outcomes were collected over a period of 30 days. Participants attended the 135 laboratory on Day 0, 2, and 5. Baseline questionnaire data were collected on Day 0. Pressure 136 pain thresholds, PAF and CME were measured on Day 0, 2 and 5. PAF was obtained via a 5-137 minute eyes-closed resting-state EEG recording from 63 electrodes. Sensorimotor PAF was 138 computed by identifying the component in the signal (transformed by independent 139 component analysis) that had a clear alpha peak (8-12Hz) upon frequency decomposition and 140 a scalp topography suggestive of a sensorimotor source. CME was obtained using 141 transcranial magnetic stimulation (TMS) mapping; single pulses of TMS delivered to the left 142 primary motor cortex (M1), and motor evoked potentials (MEPs) recorded from the right 143 masseter muscle using electromyography (EMG) electrodes. TMS was delivered at each site 144 on a 1cm-spaced grid superimposed over the scalp, and a map of the corticomotor 145 representation of the masseter muscle was generated. Corticomotor excitability was indexed 146 as map volume, which is calculated by summing MEP amplitudes from all "active sites" on 147 the grid. NGF was injected into the right masseter muscle at the end of the Day 0 and 2 148 laboratory sessions. Electronic pain diaries were collected from Days 1 to 30 at 10am and 149 7pm each day, where participant rated their pain (0-10) during various activities. Pain upon functional jaw movement is a key criterion for the diagnosis of TMD³⁰ and pain during 150 151 chewing and yawning are higher compared to other activities after an NGF injection to the masseter muscle^{28,31}. As such, the primary outcomes were pain upon chewing and yawning. 152 153 The protocol and methodology are shown in Figure 1A and 1B.

154 Analytical Validation Plan

Division of the Data. Analysis was conducted in R, MATLAB and Python, with code
 publicly available <u>https://github.com/DrNahianC/PREDICT_Scripts</u>. Figure 1C details the

It is made available under a CC-BY-NC-ND 4.0 International license .

analysis plan. We adopted a nested-control-testing scheme by partitioning 150 participants
into the first 100 (training set) and second 50 (test set) individuals to participate in the study.

Growth Mixture Modelling. We used growth mixture modelling (GMM) in R³²⁻³⁴ to 159 160 form two classes: high and low pain sensitive. For this categorization, we used the sum of 161 pain upon chewing and yawning data, and pain data from Days 1-7, as this was the timeframe 162 when pain was most prominent (eFigure 3). As such, participants would more reliably fall 163 into high and low pain sensitive classes during this timeframe. The first and last 40 164 participants (80 in total) in the training set, based on the ordering of probabilities of the pain 165 intensity trajectory belonging to one of the classes, were labelled as high and low pain 166 sensitive. The trained GMM model, once established, was locked and utilized to label the test 167 set. Consequently 38 out of 50 test set participants were labelled, with a different proportion 168 of high and low pain sensitive (24 high and 14 low pain) compared to the training set since 169 the classifications were based on the probability thresholds established in the training set. 170 These labels were recorded for subsequent comparison with the predicted labels produced by 171 the trained machine learning model.

172 Machine Learning Model Selection and Fine Tuning. We utilized five machine 173 learning models on the labelled training set -logistic regression, random forest, gradient 174 boosting, support vector machine, and neural network. The dependent variable was pain 175 sensitivity label (high/low) identified from the GMM and independent variables were 176 sensorimotor PAF and Δ CME: the latter was typified as facilitator and depressor, depending 177 on whether they showed an increase or decrease in map volume on Day 5 relative to Day 0, 178 respectively. For each model, we identified optimized parameters through 5-fold cross-179 validation: we randomly divided the 80 participants into an internal training set of 64 180 participants (consisting of four equal folds of 16) and a validation set of 16. The optimized 181 models in the internal training set were then employed to predict labels in the validation set to medRxiv preprint doi: https://doi.org/10.1101/2024.06.16.24309005; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

facilitate model selection. The model with the best performance (area under the curve) on thevalidation set was then locked in.

184	Test Set Prediction. The locked machine learning model was assessed on the test set.
185	The participant IDs in this set did not coincide with those in the pain diary data, thereby
186	preserving the double-blind nature of the analysis. By using the ground-truth labels
187	(shuffled), predicted labels (unshuffled), and the shuffling order for the test set, we were able
188	to evaluate the model's performance by comparing the reordered predicted labels against the
189	ground-truth labels established by the GMM. Performance was assessed via receiver
190	operating characteristic (ROC) area under the curve (AUC), with 95% confidence intervals
191	reported. AUC values between 0.7-0.8, 0.8-0.9 and 0.9-1 were considered "acceptable",
192	"excellent", and "outstanding" respectively ²⁹ .
193	
194	Results
195	PAF/CME demonstrated good-excellent test-retest reliability
195 196	PAF/CME demonstrated good-excellent test-retest reliability PAF and \triangle CME showed good to excellent test-retest reliability across sessions
195 196 197	PAF/CME demonstrated good-excellent test-retest reliability PAF and ΔCME showed good to excellent test-retest reliability across sessions (eFigures 5 and 7).
195 196 197 198	PAF/CME demonstrated good-excellent test-retest reliability PAF and ΔCME showed good to excellent test-retest reliability across sessions (eFigures 5 and 7). Outstanding performance on the training validation set
195 196 197 198 199	 PAF/CME demonstrated good-excellent test-retest reliability PAF and ΔCME showed good to excellent test-retest reliability across sessions (eFigures 5 and 7). Outstanding performance on the training validation set Figure 2A shows the pain scores for participants in the training and test set classified
195 196 197 198 199 200	PAF/CME demonstrated good-excellent test-retest reliabilityPAF and ΔCME showed good to excellent test-retest reliability across sessions(eFigures 5 and 7).Outstanding performance on the training validation setFigure 2A shows the pain scores for participants in the training and test set classifiedas high and low pain sensitive. Figure 2B (upper) shows the performances of the models
195 196 197 198 199 200 201	PAF/CME demonstrated good-excellent test-retest reliability PAF and ΔCME showed good to excellent test-retest reliability across sessions (eFigures 5 and 7). Outstanding performance on the training validation set Figure 2A shows the pain scores for participants in the training and test set classified as high and low pain sensitive. Figure 2B (upper) shows the performances of the models across the internal training and validation sets. Logistic regression was the winning classifier
195 196 197 198 199 200 201 202	PAF/CME demonstrated good-excellent test-retest reliability PAF and ΔCME showed good to excellent test-retest reliability across sessions (eFigures 5 and 7). Outstanding performance on the training validation set Figure 2A shows the pain scores for participants in the training and test set classified as high and low pain sensitive. Figure 2B (upper) shows the performances of the models across the internal training and validation sets. Logistic regression was the winning classifier based on its outstanding performance (AUC=1.00[1.00-1.00]) when applied to the validation
195 196 197 198 199 200 201 202 202 203	PAF/CME demonstrated good-excellent test-retest reliability PAF and ΔCME showed good to excellent test-retest reliability across sessions (eFigures 5 and 7). Outstanding performance on the training validation set Figure 2A shows the pain scores for participants in the training and test set classified as high and low pain sensitive. Figure 2B (upper) shows the performances of the models across the internal training and validation sets. Logistic regression was the winning classifier based on its outstanding performance (AUC=1.00[1.00-1.00]) when applied to the validation set (Figure 2B lower), with slower PAF and CME depression predicting higher pain with
195 196 197 198 199 200 201 202 203 203 204	PAF/CME demonstrated good-excellent test-retest reliability PAF and ΔCME showed good to excellent test-retest reliability across sessions (eFigures 5 and 7). Outstanding performance on the training validation set Figure 2A shows the pain scores for participants in the training and test set classified as high and low pain sensitive. Figure 2B (upper) shows the performances of the models across the internal training and validation sets. Logistic regression was the winning classifier based on its outstanding performance (AUC=1.00[1.00-1.00]) when applied to the validation set (Figure 2B lower), with slower PAF and CME depression predicting higher pain with regression coefficients of -1.25 and -1.27 for PAF and CME respectively.

It is made available under a CC-BY-NC-ND 4.0 International license .

205 Excellent performance on the test set

206	When the locked logistic regression model was applied to the test set, performance
207	(Figure 2C upper) was excellent (AUC=0.88[0.78-0.99]). The optimal probability threshold
208	for being classified as high pain sensitive was 0.40, with an associated sensitivity of 0.875
209	and specificity of 0.79. Applying this 0.40 probability threshold to our data, to be labelled as
210	high pain sensitive, a facilitator would need a PAF<9.56, and a depressor would need a
211	PAF<10.57. Figure 2C (lower) shows the differences in pain scores between participants
212	predicted to have high or low pain. Visually one can observe slower PAF in those predicted
213	to have high vs. low pain sensitivity (Figure 2D), This was statistically significant according
214	to a two-sample t-test ($t(48)=5.8$, $p<.001$). Moreover, one can observe a decrease in CME
215	within the masseter motor maps in those predicted to have high pain (Figure 2E), whereas
216	those predicted to have low pain exhibited an increase in CME. The differences in ΔCME
217	between these groups was statistically significant ($t(48)=2.81$, $p=.007$).
218	A benefit for a <i>combined</i> signature
219	We reran the models to determine whether the combined PAF/CME signature out-
220	performed each measure individually (eFigure 10). The performance of the PAF-only logistic
221	regression model on the training validation and test set were respectively excellent
222	(AUC=0.95[0.84-1.00]) and outstanding (AUC=0.83[0.70-0.96]). The performance of the
223	CME-only logistic regression model for the training validation and test set were respectively
224	excellent (AUC=0.88[0.69-1.00]) and acceptable (AUC=0.75[0.60-0.91]).
225	Inclusion of covariates did not improve model performance
226	We evaluated the performance of the biomarker combined with covariates. As there
	1

values when associating predictors and labels, and using parameter tuning to optimize the

It is made available under a CC-BY-NC-ND 4.0 International license .

229	coefficients associated with the filtered features. Five features were subsequently selected and
230	optimized - Sensorimotor PAF, CME, Sex, Pain Catastrophizing Scale (PCS) Total and PCS
231	Helplessness. The associations between labels and biomarkers/covariates in the training vs.
232	test set, and performance of the models are shown in Figure 3A and 3B. When including
233	these five features, the performance of the logistic regression model (regression coefficients
234	of -0.86, -0.69, 0.64, 0.02 and 0.06 for PAF, CME, Sex, PCS Total and PCS Helplessness
235	respectively) was outstanding (AUC=1.00[1.00-1.00]) and excellent (AUC=0.81[0.67-0.95])
236	for the training validation and test set were respectively. Thus, the model with biomarkers
237	only outperformed the model including covariates.
238	Results were reproducible across methodological choices
239	To determine whether our results were robust across different methodological
240	choices, we repeated the analysis using different PAF calculation methods, including
241	component level data (with the sensorimotor component chosen manually or using an
242	automated script) vs. sensor level data (with a sensorimotor region of interest), using different
243	frequency windows (8-12Hz vs. 9-11Hz) and using different CME calculation methods (map
244	volume vs. map area). We found that, regardless of the choices, logistic regression was the
245	best or equal-best performing model when applied to the training-validation set (Figure 3C),
246	with AUCs varying from acceptable (AUC=0.77) to outstanding (AUC=1.00). When the
247	locked models were applied to the test set, performance varied from acceptable (AUC=0.73)
248	to excellent (AUC=0.88) (Figure 3D). Lastly, excellent performance was demonstrated when
249	the data was analysed two other ways (eFigure 11 and 12): where GMM pain labels were
250	established using the whole 30 days rather than the first 7 days (training validation

AUC=0.84[0.64-1], test AUC =0.89[0.79-0.99]), and when missing pain diary data was not

252 imputed (training validation AUC=0.81[0.6-1], test AUC=0.89[0.79-0.99]).

It is made available under a CC-BY-NC-ND 4.0 International license .

253

Discussion

254	A full-scale analytical validation of the PAF and CME biomarker signature was
255	conducted using a prolonged pain model. In an initial training set (n=100), we found that a
256	logistic regression was the optimal classifier based on its outstanding performance
257	(AUC=100%), with slower PAF and CME depression predicting higher pain. When this
258	model was applied to an independent test set, the AUC was excellent (AUC=88%).
259	PAF/CME showed good-excellent test-retest reliability, and results were reproduced across a
260	range of methodological parameters. Inclusion of covariates did not improve model
261	performance, suggesting the model including biomarkers only was more robust. Overall, the
262	combination of sample size, pain model validity, and biomarker accuracy, reproducibility and
263	reliability suggest the PAF/CME biomarker signature has substantial potential for clinical
264	translation.
265	Our results suggest that individuals who have slow PAF prior to an anticipated
266	prolonged pain episode and show corticomotor depression during a prolonged pain episode,
267	are more likely to experience higher pain. Model performance was higher combining the two,
268	suggesting consideration of both ascending sensory and descending motor pain processing
269	mechanisms provides more information regarding pain sensitivity. Note that our study used a
270	cohort of healthy participants with strict inclusion/exclusion criteria and an experimental pain
271	model. While this may limit generalizability to clinical populations, the use of a standardized
272	sample/design is a requirement of pre-clinical analytical validation, and an essential first step
273	in the discovery pipeline toward a clinical biomarker signature. Moreover, there is already
274	evidence that the proposed biomarker is generalizable to clinical contexts. A recent study

showed that individuals with slower PAF experienced more pain following a thoracotomy 20 .

- 276 Furthermore, individuals with lower CME during the acute stages of low back pain were
- 277 more likely to develop chronic pain at 6-months follow-up³⁵. This suggests PAF and CME

It is made available under a CC-BY-NC-ND 4.0 International license .

278	shows promise in being used in pre-operative and/or post-operative/post-injury contexts to
279	classify high or low pain sensitive individuals. Given that higher acute pain predicts the
280	development of chronic pain ²⁴ PAF and CME could potentially be used as susceptibility
281	biomarkers for the transition from acute to chronic pain.

282	There are several aspects of our study which stand out. The first is sample size: with
283	recent advancements in machine learning, it has become possible to conduct analytical
284	validation of pain biomarkers. However, deep learning requires a large amount of labelled
285	samples to conduct rigorous training on validation and test sets ⁸ . Unfortunately, many pain
286	susceptibility biomarker studies have not been sufficiently sampled to adopt such
287	approaches ^{9,10} , and the ones that have used machine learning failed to reach the sample sizes
288	similar to that of the present study ^{$1,2$} .

289 Another strength of our findings is reproducibility. Previous work has shown similar 290 associations between slower PAF and higher upper limb pain, post-operative thoracic pain and chronic pain in various body regions^{17,19,20} as well as CME depression and higher upper 291 limb pain, chronic patellofemoral pain and development of chronic low back pain^{22,23,36,37}. 292 293 The present study replicated these results in a model of jaw pain, suggesting the biomarker 294 signature may be generalizable to pain more broadly. Note that some studies have not shown a negative relationship between PAF and pain sensitivity^{38,39} or a positive relationship 295 between CME depression and pain sensitivity³¹. However, these studies were not sufficiently 296 297 sampled to conduct analytical validation of the kind presented in this study. Nonetheless, the mixed findings could also arise from differences in methodological choices in the estimation 298 of PAF e.g. frequency windows³⁹ and use of sensor vs. component space data⁴⁰ and 299 estimation of CME e.g. map volume²² vs. area³¹. For this reason, we repeated the main 300 301 analysis using different methodological choices and found at least acceptable AUCs, 302 supporting the reproducibility of our results.

It is made available under a CC-BY-NC-ND 4.0 International license .

303	The PAF/CME measures demonstrated good-excellent reliability. Reliability is a
304	desirable characteristic which assists in the widespread application of pain biomarkers ⁸ . We
305	found that participants exhibit stable PAF across days despite the presence of pain, and even
306	when considering different methodological factors that may influence the reliability such as
307	pre-processing pipeline, recording length and frequency window ¹⁴ . Indeed, reliable PAF was
308	found with a recording length as short as 2 minutes and minimal data pre-processing. We also
309	showed that those who show CME depression on Day 2 are also likely to show CME
310	depression on Day 5 (and vice versa for those who show CME facilitation). This was shown
311	even when an automated method of determining MEP amplitude on each trial was applied.
312	Thus, our work not only shows that PAF and CME can predict pain, but the relative ease with
313	which reliable PAF/CME data can be obtained is promising for subsequent clinical
314	translation.
315	Another strength of this study is our pain model. While other pain biomarker studies
316	have shown promising results, these studies were restricted to pain models utilizing transient
316 317	have shown promising results, these studies were restricted to pain models utilizing transient painful stimuli lasting seconds to minutes ¹¹⁻¹³ . The brief nature of the painful stimuli
316 317 318	have shown promising results, these studies were restricted to pain models utilizing transient painful stimuli lasting seconds to minutes ¹¹⁻¹³ . The brief nature of the painful stimuli questions the external validity of these findings and limits generalizability to clinical
316 317 318 319	 have shown promising results, these studies were restricted to pain models utilizing transient painful stimuli lasting seconds to minutes¹¹⁻¹³. The brief nature of the painful stimuli questions the external validity of these findings and limits generalizability to clinical populations. In contrast, the present study used a prolonged pain model lasting weeks.
316317318319320	 have shown promising results, these studies were restricted to pain models utilizing transient painful stimuli lasting seconds to minutes¹¹⁻¹³. The brief nature of the painful stimuli questions the external validity of these findings and limits generalizability to clinical populations. In contrast, the present study used a prolonged pain model lasting weeks. Several other studies have shown that injections of NGF to the neck, elbow or masseter
 316 317 318 319 320 321 	 have shown promising results, these studies were restricted to pain models utilizing transient painful stimuli lasting seconds to minutes¹¹⁻¹³. The brief nature of the painful stimuli questions the external validity of these findings and limits generalizability to clinical populations. In contrast, the present study used a prolonged pain model lasting weeks. Several other studies have shown that injections of NGF to the neck, elbow or masseter muscles can mimic symptoms of clinical neck pain⁴¹, chronic lateral epicondylalgia²⁷ and
 316 317 318 319 320 321 322 	 have shown promising results, these studies were restricted to pain models utilizing transient painful stimuli lasting seconds to minutes¹¹⁻¹³. The brief nature of the painful stimuli questions the external validity of these findings and limits generalizability to clinical populations. In contrast, the present study used a prolonged pain model lasting weeks. Several other studies have shown that injections of NGF to the neck, elbow or masseter muscles can mimic symptoms of clinical neck pain⁴¹, chronic lateral epicondylalgia²⁷ and TMD²⁸ respectively. Thus, the observed relationships between PAF/CME and pain in the
 316 317 318 319 320 321 322 323 	 have shown promising results, these studies were restricted to pain models utilizing transient painful stimuli lasting seconds to minutes¹¹⁻¹³. The brief nature of the painful stimuli questions the external validity of these findings and limits generalizability to clinical populations. In contrast, the present study used a prolonged pain model lasting weeks. Several other studies have shown that injections of NGF to the neck, elbow or masseter muscles can mimic symptoms of clinical neck pain⁴¹, chronic lateral epicondylalgia²⁷ and TMD²⁸ respectively. Thus, the observed relationships between PAF/CME and pain in the present study show promise in terms of clinical applicability.
 316 317 318 319 320 321 322 323 324 	have shown promising results, these studies were restricted to pain models utilizing transient painful stimuli lasting seconds to minutes ¹¹⁻¹³ . The brief nature of the painful stimuli questions the external validity of these findings and limits generalizability to clinical populations. In contrast, the present study used a prolonged pain model lasting weeks. Several other studies have shown that injections of NGF to the neck, elbow or masseter muscles can mimic symptoms of clinical neck pain ⁴¹ , chronic lateral epicondylalgia ²⁷ and TMD ²⁸ respectively. Thus, the observed relationships between PAF/CME and pain in the present study show promise in terms of clinical applicability. Lastly, the PAF/CME biomarker demonstrated high performance. A previous study

acute low back pain patients (pain duration 6-12 weeks) could predict future pain persistence

327 at ~7, 29 and 54 weeks, with AUCs of $67-83\%^{1}$. Another study on 24 sub-acute low back

It is made available under a	CC-BY-NC-ND 4.0	International license
------------------------------	-----------------	-----------------------

- 328 pain patients showed that white matter fractional anisotropy measures in the superior
- 329 longitudinal fasciculus and internal capsule predicted pain persistence over the next year,
- with an AUC of $81\%^2$. Though the present did not directly assess the transition to chronic
- pain, our AUCs of 100% (validation set) and 88% (test set) appear comparatively high. We
- therefore encourage future clinical studies to determine whether PAF/CME can predict the
- transition from acute to chronic pain.

334 Conclusions

- A novel biomarker signature comprised of PAF and CME accurately and reliably
- distinguishes high and low pain sensitive individuals during prolonged jaw pain with an
- excellent AUC of 88% in an independent test set. No other pain biomarker study has shown
- this combination of biomarker accuracy, reproducibility, reliability and pain model validity,
- 339 suggesting high potential for clinical translation.

340 Acknowlegements

341 This project was funded by the National Institutes of Health (R61 NS113269/NS/NINDS thH

342 HHS/United States). Clinical Trial Registration: NCT04241562

- 343 <u>https://classic.clinicaltrials.gov/ct2/show/results/NCT04241562?view=results.</u>
- 344 The authors have no conflicts to declare. The corresponding author had full access to all the
- 345 data in the study and takes responsibility for the integrity of the data and accuracy of the data
- analysis. The data supporting the findings of this study are available from the corresponding
- 347 author upon reasonable request.
- 348
- 349
- 350
- 351
- 352
- 353

It is made available under a CC-BY-NC-ND 4.0 International license .

355

References

356	1. Baliki MN, Petre B, Torbey S, et al. Corticostriatal functional connectivity predicts transition
357	to chronic back pain. <i>Nature neuroscience</i> . 2012;15(8):1117-1119.
358	2. Mansour AR, Baliki MN, Huang L, et al. Brain white matter structural properties predict
359	transition to chronic pain. <i>PAIN</i> [®] . 2013;154(10):2160-2168.
360	3. Vachon-Presseau E, Tétreault P, Petre B, et al. Corticolimbic anatomical characteristics
361	predetermine risk for chronic pain. Brain. 2016;139(7):1958-1970.
362	4. Green A, Wang S, Stein J, et al. Neural signatures in patients with neuropathic pain.
202	Neurology. 2009, 72(0).509-571.
364 365	genome-wide serum microRNA expression analysis as noninvasive biomarkers for endometriosis.
366	The Journal of Clinical Endocrinology & Metabolism 2013;98(1);281-289
367	6. Singh JA. Noorbaloochi S. Knutson KL. Cytokine and neuropeptide levels are associated with
368	pain relief in patients with chronically painful total knee arthroplasty: a pilot study. BMC
369	Musculoskeletal Disorders. 2017:18(1):1-6.
370	7 Sasamoto N. Zeleznik OA. Vitonis AE. et al. Presurgical blood metabolites and risk of
371	nostsurgical nelvic nain in young natients with endometricsis. <i>Fertility and Sterility</i>
372	2022:117(6):1235-1245.
373	8. Zhang Z. Gewandter JS. Geha P. Brain imaging biomarkers for chronic pain. <i>Frontiers in</i>
374	Neurology 2022:12:734821
375	9. Sluka KA. Wager TD. Sutherland SP. et al. Predicting chronic postsurgical pain: current
376	evidence and a novel program to develop predictive biomarker signatures <i>Pain</i> 2023:164(9):1912-
377	1926
378	10. Eldabe S. Obara I. Panwar C. Caraway D. Biomarkers for chronic pain: significance and
379	summary of recent advances. Pain Research and Management, 2022-2022
380	11. Lee I-J. Kim HJ. Čeko M. et al. A neuroimaging biomarker for sustained experimental and
381	clinical pain. Nature medicine. 2021:27(1):174-182.
382	12. Woo C-W. Schmidt L. Krishnan A. et al. Quantifying cerebral contributions to pain beyond
383	nociception. Nature communications. 2017:8(1):14211.
384	13. Wager TD, Atlas LY, Lindquist MA, Roy M, Woo C-W, Kross E. An fMRI-based neurologic
385	signature of physical pain. New England Journal of Medicine. 2013;368(15):1388-1397.
386	14. Chowdhury NS, Skippen P, Si E, et al. The reliability of two prospective cortical biomarkers
387	for pain: EEG peak alpha frequency and TMS corticomotor excitability. <i>Journal of Neuroscience</i>
388	Methods. 2023/02/01/ 2023;385:109766. doi:https://doi.org/10.1016/j.jneumeth.2022.109766
389	15. Davis KD, Aghaeepour N, Ahn AH, et al. Discovery and validation of biomarkers to aid the
390	development of safe and effective pain therapeutics: challenges and opportunities. <i>Nature Reviews</i>
391	Neurology. 2020;16(7):381-400.
392	16. van Dieen JH, Reeves NP, Kawchuk G, van Dillen LR, Hodges PW. Motor Control Changes in
393	Low Back Pain: Divergence in Presentations and Mechanisms. The Journal of orthopaedic and sports
394	physical therapy. Jun 2019;49(6):370-379. doi:10.2519/jospt.2019.7917
395	17. Furman AJ, Meeker TJ, Rietschel JC, et al. Cerebral peak alpha frequency predicts individual
396	differences in pain sensitivity. <i>NeuroImage</i> . 2018;167:203-210.
397	18. Weavil JC, Amann M. Corticospinal excitability during fatiguing whole body exercise.
398	Progress in brain research. 2018;240:219-246.
399	19. Furman AJ, Prokhorenko M, Keaser ML, et al. Sensorimotor peak alpha frequency is a
400	reliable biomarker of prolonged pain sensitivity. Cerebral Cortex. 2020;30(12):6069-6082.
401	20. Millard SK, Furman AJ, Kerr A, et al. Predicting postoperative pain in lung cancer patients
402	using preoperative peak alpha frequency. British Journal of Anaesthesia. 2022;128(6):e346-e348.
403	21. Seminowicz DA, Thapa T, Furman AJ, et al. Slow peak alpha frequency and corticomotor
404	depression linked to high pain susceptibility in transition to sustained pain. <i>bioRxiv</i> . 2018:278598.

It is made available under a CC-BY-NC-ND 4.0 International license .

405 22. Seminowicz DA, Thapa T, Schabrun SM. Corticomotor depression is associated with higher 406 pain severity in the transition to sustained pain: A longitudinal exploratory study of individual 407 differences. The Journal of Pain. 2019;20(12):1498-1506. 408 23. Chowdhury NS, Chang W-J, Millard SK, et al. The Effect of Acute and Sustained Pain on 409 Corticomotor Excitability: A Systematic Review and Meta-analysis of group-and individual-level data. 410 The Journal of Pain. 2022;23(10):1680-1696. 411 24. Hah JM, Cramer E, Hilmoe H, et al. Factors associated with acute pain estimation, 412 postoperative pain resolution, opioid cessation, and recovery: secondary analysis of a randomized 413 clinical trial. JAMA network open. 2019;2(3):e190168-e190168. 414 25. Seminowicz DA, Bilska K, Chowdhury NS, et al. A novel cortical biomarker signature for 415 predicting pain sensitivity: protocol for the PREDICT longitudinal analytical validation study. Pain 416 *Reports*. 2020;5(4) 417 26. Svensson P, Cairns BE, Wang K, Arendt-Nielsen L. Injection of nerve growth factor into 418 human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia. Pain. 419 2003;104(1-2):241-247. 420 Bergin MJG, Hirata R, Mista C, et al. Movement evoked pain and mechanical hyperalgesia 27. 421 after intramuscular injection of nerve growth factor: a model of sustained elbow pain. Pain 422 Medicine. 2015;16(11):2180-2191. 423 28. Schabrun SM, Si E, Millard SK, et al. Intramuscular injection of nerve growth factor as a 424 model of temporomandibular disorder: nature, time-course, and sex differences characterising the 425 pain experience. Neurobiology of Pain. 2023;13:100117. 426 Hosmer Jr DW, Lemeshow S, Sturdivant RX. Applied logistic regression. vol 398. John Wiley & 29. 427 Sons; 2013. 428 Schiffman E, Ohrbach R, Truelove E, et al. Diagnostic criteria for temporomandibular 30. 429 disorders (DC/TMD) for clinical and research applications: recommendations of the International 430 RDC/TMD Consortium Network and Orofacial Pain Special Interest Group. Journal of oral & facial 431 pain and headache. 2014;28(1):6. 432 31. Costa YM, Exposto FG, Kothari M, et al. Masseter corticomotor excitability is decreased after 433 intramuscular administration of nerve growth factor. Eur J Pain. Oct 2019;23(9):1619-1630. 434 doi:10.1002/ejp.1438 435 32. Proust-Lima C, Philipps V, Liquet B. Estimation of extended mixed models using latent classes 436 and latent processes: the R package lcmm. arXiv preprint arXiv:150300890. 2015; 437 Li F, Duncan TE, Duncan SC, Acock A. Latent growth modeling of longitudinal data: A finite 33. 438 growth mixture modeling approach. Structural Equation Modeling. 2001;8(4):493-530. Ram N, Grimm KJ. Methods and measures: Growth mixture modeling: A method for 439 34. 440 identifying differences in longitudinal change among unobserved groups. International journal of 441 behavioral development. 2009;33(6):565-576. 442 Jenkins LC, Chang W-J, Buscemi V, et al. Cortical function and sensorimotor plasticity are 35. 443 prognostic factors associated with future low back pain after an acute episode: the UPWaRD 444 prospective cohort study. Pain. 2022:10.1097. 445 36. Jenkins LC, Chang W-J, Buscemi V, et al. Low Somatosensory Cortex Excitability in the Acute 446 Stage of Low Back Pain Causes Chronic Pain. The Journal of Pain. 2022/02/01/ 2022;23(2):289-304. 447 doi: https://doi.org/10.1016/j.jpain.2021.08.003 448 37. Te M, Baptista AF, Chipchase LS, Schabrun SM. Primary motor cortex organization is altered 449 in persistent patellofemoral pain. Pain Medicine. 2017;18(11):2224-2234. 450 Nir R-R, Sinai A, Raz E, Sprecher E, Yarnitsky D. Pain assessment by continuous EEG: 38. association between subjective perception of tonic pain and peak frequency of alpha oscillations 451 452 during stimulation and at rest. Brain research. 2010;1344:77-86. 453 39. De Martino E, Gregoret L, Zandalasini M, Graven-Nielsen T. Slowing in peak-alpha frequency 454 recorded after experimentally-induced muscle pain is not significantly different between high and 455 low pain-sensitive subjects. The Journal of Pain. 2021;22(12):1722-1732.

It is made available under a CC-BY-NC-ND 4.0 International license .

456 457 458	40. Millard SK, Chiang AKI, Humburg P, et al. Effects of nicotine compared to placebo gum on sensitivity to pain and mediating effects of peak alpha frequency. eLife Sciences Publications, Ltd; 2023.
459 460	41. Christensen SWM, Elgueta-Cancino E, Simonsen MB, et al. Effect of prolonged experimental neck pain on exercise-induced hypoalgesia. <i>Pain</i> . 2022;163(12):2411-2420.
461	
462	
463	
464	
465	
466	
467	
468	
469	
470	
471	
472	
473	
474	
475	
476	
477	
478	

It is made available under a CC-BY-NC-ND 4.0 International license .

479

Figure Captions

480 Figure 1. Study methodology, including study design, data collection procedures and 481 analysis plan. (A) Experimental protocol showing timeline of data collection procedures. On 482 Day 0, we measured peak alpha frequency (PAF) and corticomotor excitability (CME). At 483 the end of the session, an injection of nerve growth factor (NGF) was administered to the 484 right masseter muscle. On Day 2, PAF and CME were measured, followed by a second NGF 485 injection. On Day 5, PAF and CME were measured. From Days 1-30, electronic diaries 486 measuring jaw pain were sent to participants at 10AM and 7PM each day. (B) Details of the 487 methodology. Sensorimotor PAF was measured using a 5 minutes eyes closed resting state 488 EEG recording. Sensorimotor PAF was computed by identifying the component in the signal 489 (transformed by independent component analysis) that had a clear alpha peak in the 8–12 Hz 490 range upon frequency decomposition and a scalp topography suggestive of a source 491 predominately over the sensorimotor cortex. TMS mapping was conducted by stimulating the 492 scalp area over left M1 to obtain a map of the representation of the right masseter muscle. 493 The map consists of the motor-evoked potential (MEP) amplitude at each stimulated location, 494 with CME corresponding to the map volume (sum of all MEPs from active sites). (C) Details 495 of the analysis plan. We adopted a nested-control-test scheme by partitioning the 150 subjects 496 into a training set consisting of 100 subjects and an independent test set of 50 subjects. We 497 labelled a subset of participants in the training (n = 80) and test set (n = 38) as high or low 498 pain sensitive using growth mixture modelling (GMM) to establish "ground-truth" labels. We 499 then ran various machine learning models on the labelled training set (with PAF/CME as 500 predictors, and pain severity labels as outcome), and determined optimized parameters 501 through 5-fold cross-validation i.e. randomly dividing the 80 subjects into an internal training 502 set of 64 subjects (with 4 equal folds of 16) and a validation set of 16. The optimized models in the internal training set were employed to predict labels in the validation set to facilitate 503 504 model selection. The model with the best performance on the validation set was then locked 505 in, and applied to the labelled test set, comparing the predicted labels of high/low pain 506 sensitive with the ground-truth labels of high/low pain sensitive.

507 Figure 2. Performance of the combined PAF and CME biomarker on training and test

508 set. (A) Results of the growth mixture modelling which categorized 80 participants in the 509 training set (left) and 38 participants in the test (right) as high or low pain sensitive. Data 510 shows mean pain score (chew + yawn pain rating) for each timepoint, while the shaded area shows 95% confidence intervals. (B) The upper panel shows performances (AUC [95% 511 512 confidence intervals]) of various machine learning models for the internal training set and 513 validation set. Logistic regression (LR) was chosen as the optimal classifier based on 514 outstanding AUC of 100% as shown in the lower panel. (C) The upper panel shows the 515 performance of the locked logistic regression model when applied to the test set, which was 516 in the excellent range (AUC of 88%). The lower panel shows the pain trajectories (mean 517 chew + yawn pain and 95% confidence intervals) of participants predicted to have high or 518 low pain sensitivity based on the locked logistic regression model. (D) Individual and mean 519 z-transformed spectral plots and topography of the sensorimotor alpha component on Day 0 520 for participants predicted to have high or pain sensitivity based on the locked logistic 521 regression model. (E) The mean motor cortex maps on Day 0 and Day 5 showing normalized 522 motor evoked potential (MEP) amplitude (expressed as a proportion of the maximal MEP

It is made available under a CC-BY-NC-ND 4.0 International license .

amplitude) for participants predicted to have high or low pain sensitivity based on the lockedlogistic regression model.

525

526 Figure 3. Performance of the combined PAF and CME biomarker on training and test 527 set when including covariates, and across PAF/CME calculation methods. (A) Visualisation of biomarkers and covariates for the training and test sets across high (red) and 528 529 low (blue) pain labels identified from the GMM. Data on PAF, PCS total and PCS 530 helplessness are plotted as boxplots, while data on CME and Sex are plotted according to 531 facilitator: depressor (Fac: dep) and female: male (fem: mal) split respectively, including odd 532 ratios. A lower odds ratio means a lower probability of high pain sensitive individuals 533 belonging to the facilitator or female categories. For PAF and CME, low pain was associated 534 with fast PAF and CME facilitation for both training and test sets. In contrast, the relationship 535 between covariates and labels were in the opposite direction for the training and test set, 536 suggesting the relationship between biomarkers and labels was consistent. (B) The left panel 537 shows the performance of the locked logistic regression model on the test set when including 538 covariates in the model. The right panel shows pain trajectories (mean chew + yawn score 539 and 95% confidence intervals) of participants predicted to have high or low pain sensitivity 540 based on the locked logistic regression model including covariates. (C) The performance of each machine learning model (AUC [95% confidence intervals]) on the training validation set 541 542 across different PAF/CME calculation methods. This includes the sensorimotor component 543 chosen manually after an independent component analysis, component identified using an 544 automated script after an independent component analysis, or using a sensorimotor region of 545 interest (ROI, mean of Cz, C3 and C4) in electrode space, to calculate PAF. We also looked at different frequency windows for computing PAF (8-12Hz vs. 9-11Hz) or CME calculated 546 547 using map area or map volume. (D) The performance of the locked logistic regression model 548 (AUC [95% confidence intervals]) when applied to the test set, across different PAF/CME 549 calculation methods.

550

551







Relationship between Biomarkers/Covariates and Labels

